Partnerships & collaborations
The experience and expertise we have acquired through the years have served as a basis of and fueled our own research and development programs, thanks to the discovery of new therapeutic targets, the development of novel technologies or the selection of drug-candidates that have since proven their therapeutic efficacy in clinical trials.
Partnering is in our DNA
These alliances based on mutual commitment and exchange of expertise were always placed at the heart of our pipeline. This vision has allowed us to move the programs forward capitalizing on precious skills that complement our own.
With pharmaceutical stakeholders
Together with our historical pharmaceutical partners (Sanofi, Solvay, Servier, UCB…), we have shared our know-how to select, optimize, and validate new molecules.
Within the academic community
The solid relationships we maintain with key opinion leaders in our therapeutic areas of expertise, enable us to be at the heart of the latest academic, scientific and clinical knowledge.
To continuously enhance the quality of our pipeline, we assess opportunities to collaborate with various key stakeholders that bring crossover added-value and, thanks to shared experience and expertise, that help accelerate the development of our drug candidates and diagnostic solutions.
For our programs
As a late-stage clinical biopharmaceutical company we are continuously shaping our market access strategies. We are open to alliances and partnership opportunities that would have the potential to leverage the value of our drug candidates, in vitro diagnostic (biomarker) program and thus facilitating their availability to patients with high unmet needs, and to carry out our disease awareness initiatives.
For your programs
Whether you are in a industry, academic research institution and/or advocacy group setting, we are always available to discuss with you collaboration opportunities in our therapeutic areas of expertise.